-
Je něco špatně v tomto záznamu ?
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
A. Younes, P. Hilden, B. Coiffier, A. Hagenbeek, G. Salles, W. Wilson, JF. Seymour, K. Kelly, J. Gribben, M. Pfreunschuh, F. Morschhauser, H. Schoder, AD. Zelenetz, J. Rademaker, R. Advani, N. Valente, C. Fortpied, TE. Witzig, LH. Sehn, A....
Jazyk angličtina Země Velká Británie
Typ dokumentu konsensus - konference, časopisecké články, směrnice pro lékařskou praxi, přehledy
PubMed
28379322
DOI
10.1093/annonc/mdx097
Knihovny.cz E-zdroje
- MeSH
- časové faktory MeSH
- fluorodeoxyglukosa F18 aplikace a dávkování MeSH
- konsensus MeSH
- kontrastní látky aplikace a dávkování MeSH
- kritéria léčebné odpovědi * MeSH
- lidé MeSH
- nehodgkinský lymfom diagnostické zobrazování farmakoterapie mortalita patologie MeSH
- počítačová rentgenová tomografie normy MeSH
- pozitronová emisní tomografie normy MeSH
- prediktivní hodnota testů MeSH
- přežití bez známek nemoci MeSH
- progrese nemoci MeSH
- protinádorové látky škodlivé účinky terapeutické užití MeSH
- staging nádorů MeSH
- stanovení cílového parametru MeSH
- tumor burden MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- konsensus - konference MeSH
- přehledy MeSH
- směrnice pro lékařskou praxi MeSH
In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
Academic Medical Center Amsterdam The Netherlands
Academic Medical Center University of Amsterdam Amsterdam The Netherlands
Biostatistics Memorial Sloan Kettering Cancer Center New York USA
British Columbia Cancer Agency Vancouver Canada
Children's National Health System Washington USA
Cleveland Clinic Cleveland USA
Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital New York
Department of Diagnostic Medicine University of Modena Modena Italy
Department of Haemato Oncology Barts Cancer Institute London UK
Department of Hematology National Cancer Center Hospital Tokyo Japan
Department of Hematology Université de Lille 2 Lille France
Department of Hematology University Hospital Centre Zagreb Zagreb Croatia
Department of Hematology University of Bologna Bologna
Department of Hematology University of Copenhagen Denmark
Department of Internal Medicine Universität des Saarlandes Homburg Germany
Department of Internal Medicine University Hospital of Cologne Cologne Germany
Department of Oncology Stanford University Stanford
Department of Radiology Memorial Sloan Kettering Cancer Center New York
Division of Medical Oncology and Hematology Princess Margaret Cancer Centre Toronto Canada
Fox Chase Cancer Center Philadelphia USA
Fred Hutchinson Cancer Research Center Seattle USA
Haemato Oncology Hôpital Saint Louis Paris France
Haematology Department Plymouth University UK
Hematology Université Lyon 1 Lyon Sud Charles Mérieux Lyon France
Janssen Research and Development Spring House USA
John Theurer Cancer Center Hackensack University Medical Center Hackensack
Lymphoid Malignancies Branch National Cancer Institute Bethesda USA
Lymphoma and Stem Cell Transplantation Program Charles University Prague Czech Republic
Massachusetts General Hospital Center for Lymphoma Boston
Medicine Clinic 3 Ludwig Maximilian University Munich Germany
Nuclear Medicine Hôpitaux Universitaires Henri Mondor Créteil France
Pediatrics Department Roswell Park Cancer Institute Buffalo USA
Peter MacCallum Cancer Centre and University of Melbourne Australia
Servier Neuilly sur Seine France
Statistics EORTC Brussels Belgium
U T M D Anderson Cancer Center Houston
University of Michigan Comprehensive Cancer Center Ann Arbor USA
University of Pennsylvania School of Medicine Philadelphia USA
Weill Cornell Medicine and and New York Presbyterian Hospital New York
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18010700
- 003
- CZ-PrNML
- 005
- 20240313104218.0
- 007
- ta
- 008
- 180404s2017 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/annonc/mdx097 $2 doi
- 035 __
- $a (PubMed)28379322
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Younes, A $u Lymphoma Service.
- 245 10
- $a International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017) / $c A. Younes, P. Hilden, B. Coiffier, A. Hagenbeek, G. Salles, W. Wilson, JF. Seymour, K. Kelly, J. Gribben, M. Pfreunschuh, F. Morschhauser, H. Schoder, AD. Zelenetz, J. Rademaker, R. Advani, N. Valente, C. Fortpied, TE. Witzig, LH. Sehn, A. Engert, RI. Fisher, PL. Zinzani, M. Federico, M. Hutchings, C. Bollard, M. Trneny, YA. Elsayed, K. Tobinai, JS. Abramson, N. Fowler, A. Goy, M. Smith, S. Ansell, J. Kuruvilla, M. Dreyling, C. Thieblemont, RF. Little, I. Aurer, MHJ. Van Oers, K. Takeshita, A. Gopal, S. Rule, S. de Vos, I. Kloos, MS. Kaminski, M. Meignan, LH. Schwartz, JP. Leonard, SJ. Schuster, VE. Seshan,
- 520 9_
- $a In recent years, the number of approved and investigational agents that can be safely administered for the treatment of lymphoma patients for a prolonged period of time has substantially increased. Many of these novel agents are evaluated in early-phase clinical trials in patients with a wide range of malignancies, including solid tumors and lymphoma. Furthermore, with the advances in genome sequencing, new "basket" clinical trial designs have emerged that select patients based on the presence of specific genetic alterations across different types of solid tumors and lymphoma. The standard response criteria currently in use for lymphoma are the Lugano Criteria which are based on [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography or bidimensional tumor measurements on computerized tomography scans. These differ from the RECIST criteria used in solid tumors, which use unidimensional measurements. The RECIL group hypothesized that single-dimension measurement could be used to assess response to therapy in lymphoma patients, producing results similar to the standard criteria. We tested this hypothesis by analyzing 47 828 imaging measurements from 2983 individual adult and pediatric lymphoma patients enrolled on 10 multicenter clinical trials and developed new lymphoma response criteria (RECIL 2017). We demonstrate that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions. Furthermore, we introduced a new provisional category of a minor response. We also clarified response assessment in patients receiving novel immune therapy and targeted agents that generate unique imaging situations.
- 650 _2
- $a protinádorové látky $x škodlivé účinky $x terapeutické užití $7 D000970
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a kontrastní látky $x aplikace a dávkování $7 D003287
- 650 _2
- $a progrese nemoci $7 D018450
- 650 _2
- $a přežití bez známek nemoci $7 D018572
- 650 _2
- $a stanovení cílového parametru $7 D023381
- 650 _2
- $a fluorodeoxyglukosa F18 $x aplikace a dávkování $7 D019788
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nehodgkinský lymfom $x diagnostické zobrazování $x farmakoterapie $x mortalita $x patologie $7 D008228
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a pozitronová emisní tomografie $x normy $7 D049268
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 12
- $a kritéria léčebné odpovědi $7 D066066
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a počítačová rentgenová tomografie $x normy $7 D014057
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a tumor burden $7 D047368
- 655 _2
- $a konsensus - konference $7 D016446
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a směrnice pro lékařskou praxi $7 D017065
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Hilden, P $u Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA.
- 700 1_
- $a Coiffier, Bertrand, $d 1947-2019 $u Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France. $7 xx0314848
- 700 1_
- $a Hagenbeek, A $u Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
- 700 1_
- $a Salles, G $u Hematology, Université Lyon-1, Lyon-Sud Charles Mérieux, Lyon, France.
- 700 1_
- $a Wilson, W $u Lymphoid Malignancies Branch, National Cancer Institute, Bethesda, USA.
- 700 1_
- $a Seymour, J F $u Peter MacCallum Cancer Centre and University of Melbourne, Australia.
- 700 1_
- $a Kelly, K $u Pediatrics Department, Roswell-Park Cancer Institute, Buffalo, USA.
- 700 1_
- $a Gribben, J $u Department of Haemato-Oncology, Barts Cancer Institute, London, UK.
- 700 1_
- $a Pfreunschuh, M $u Department of Internal Medicine, Universität des Saarlandes, Homburg, Germany.
- 700 1_
- $a Morschhauser, F $u Department of Hematology, Université de Lille 2, Lille, France.
- 700 1_
- $a Schoder, H $u Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York.
- 700 1_
- $a Zelenetz, A D $u Lymphoma Service.
- 700 1_
- $a Rademaker, J $u Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York.
- 700 1_
- $a Advani, R $u Department of Oncology, Stanford University, Stanford.
- 700 1_
- $a Valente, N $u Genentech, San Francisco, USA.
- 700 1_
- $a Fortpied, C $u Statistics, EORTC, Brussels, Belgium.
- 700 1_
- $a Witzig, T E $u Mayo Clinic, Rochester, USA.
- 700 1_
- $a Sehn, L H $u British Columbia Cancer Agency, Vancouver, Canada.
- 700 1_
- $a Engert, A $u Department of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
- 700 1_
- $a Fisher, R I $u Fox Chase Cancer Center, Philadelphia, USA.
- 700 1_
- $a Zinzani, Pier Luigi, $d 1959- $u Department of Hematology, University of Bologna, Bologna. $7 xx0314852
- 700 1_
- $a Federico, M $u Department of Diagnostic Medicine, University of Modena, Modena, Italy.
- 700 1_
- $a Hutchings, M $u Department of Hematology, University of Copenhagen, Denmark.
- 700 1_
- $a Bollard, C $u Children's National Health System, Washington, USA.
- 700 1_
- $a Trneny, M $u Lymphoma and Stem Cell Transplantation Program, Charles University, Prague, Czech Republic.
- 700 1_
- $a Elsayed, Y A $u Janssen Research & Development, Spring House, USA.
- 700 1_
- $a Tobinai, K $u Department of Hematology, National Cancer Center Hospital, Tokyo, Japan.
- 700 1_
- $a Abramson, J S $u Massachusetts General Hospital, Center for Lymphoma, Boston.
- 700 1_
- $a Fowler, N $u U.T. M.D.Anderson Cancer Center, Houston.
- 700 1_
- $a Goy, A $u John Theurer Cancer Center, Hackensack University Medical Center, Hackensack.
- 700 1_
- $a Smith, M $u Cleveland Clinic, Cleveland, USA.
- 700 1_
- $a Ansell, S $u Mayo Clinic, Rochester, USA.
- 700 1_
- $a Kuruvilla, J $u Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
- 700 1_
- $a Dreyling, M $u Medicine Clinic III, Ludwig Maximilian University, Munich, Germany.
- 700 1_
- $a Thieblemont, C $u Haemato-Oncology, Hôpital Saint Louis, Paris, France.
- 700 1_
- $a Little, R F $u Divisions of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, USA.
- 700 1_
- $a Aurer, I $u Department of Hematology, University Hospital Centre Zagreb, Zagreb, Croatia.
- 700 1_
- $a Van Oers, M H J $u Academic Medical Center, Amsterdam, The Netherlands.
- 700 1_
- $a Takeshita, K $u Celgene, Summit.
- 700 1_
- $a Gopal, A $u Fred Hutchinson Cancer Research Center, Seattle, USA.
- 700 1_
- $a Rule, S $u Haematology Department, Plymouth University, UK.
- 700 1_
- $a de Vos, S $u Oncology, UCLA, Los Angeles, USA.
- 700 1_
- $a Kloos, I $u Servier, Neuilly sur Seine, France.
- 700 1_
- $a Kaminski, M S $u University of Michigan Comprehensive Cancer Center, Ann Arbor, USA.
- 700 1_
- $a Meignan, M $u Nuclear Medicine, Hôpitaux Universitaires Henri Mondor, Créteil, France.
- 700 1_
- $a Schwartz, L H $u Columbia University College of Physicians and Surgeons and New York Presbyterian Hospital, New York.
- 700 1_
- $a Leonard, J P $u Weill Cornell Medicine and and New York Presbyterian Hospital, New York.
- 700 1_
- $a Schuster, S J $u University of Pennsylvania School of Medicine, Philadelphia, USA.
- 700 1_
- $a Seshan, V E $u Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA.
- 773 0_
- $w MED00000432 $t Annals of oncology $x 1569-8041 $g Roč. 28, č. 7 (2017), s. 1436-1447
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28379322 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180404 $b ABA008
- 991 __
- $a 20240313104213 $b ABA008
- 999 __
- $a ok $b bmc $g 1288185 $s 1007512
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 28 $c 7 $d 1436-1447 $i 1569-8041 $m Annals of oncology $n Ann Oncol $x MED00000432
- LZP __
- $a Pubmed-20180404
